On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) opened higher 54.92% from the last session, before settling in for the closing price of $2.44. Price fluctuations for CRDF have ranged from $1.25 to $6.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 9.26% over the last five years. Company’s average yearly earnings per share was noted -7.10% at the time writing. With a float of $47.17 million, this company’s outstanding shares have now reached $48.73 million.
The firm has a total of 32 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cardiff Oncology Inc is 7.76%, while institutional ownership is 24.93%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.10% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Check out the current performance indicators for Cardiff Oncology Inc (CRDF). In the past quarter, the stock posted a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 280.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Analysing the last 5-days average volume posted by the [Cardiff Oncology Inc, CRDF], we can find that recorded value of 10.23 million was better than the volume posted last year of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 44.64%. Additionally, its Average True Range was 0.34.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 74.68%, which indicates a significant decrease from 80.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 187.02% in the past 14 days, which was higher than the 110.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.83, while its 200-day Moving Average is $3.15. Now, the first resistance to watch is $4.22. This is followed by the second major resistance level at $4.65. The third major resistance level sits at $5.16. If the price goes on to break the first support level at $3.28, it is likely to go to the next support level at $2.77. Should the price break the second support level, the third support level stands at $2.34.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are currently 51,134K shares outstanding in the company with a market cap of 193.29 million. Presently, the company’s annual sales total 490 K according to its annual income of -41,440 K. Last quarter, the company’s sales amounted to 170 K and its income totaled -11,860 K.
